ZAVICEFTA® has consistent dosing across indications, with no dosage adjustments required in the elderly, patients with mild renal impairment (estimated CrCl ≥51 to ≤80 mL/min) and those with hepatic impairment.2
*The dose of ZAVICEFTA® in patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated using the Cockcroft-Gault formula.
†To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.
‡To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.
§The total duration shown may include intravenous ZAVICEFTA® followed by appropriate oral therapy.
Dosage adjustment is required for patients with renal impairment (estimated CrCl ≤50 mL/min).2